Health & bio × Macro

Lilly's oral GLP-1 'Foundayo' ships after April 1 FDA approval

Orforglipron once-daily pill dispatched via LillyDirect. Insured patients pay $25/month; uninsured, $149–349. Highest dose showed 12% weight loss in 72-week trial (placebo 0.9%). Heads directly into competition with Novo's Wegovy pill.

Primary sources · 2
CNBCBioPharma Dive
← View the full 2026-04-07 (Tue) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →